Literature DB >> 10639369

Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose.

J L Rodríguez-Tudela1, F Martín-Díez, M Cuenca-Estrella, L Rodero, Y Carpintero, B Gorgojo.   

Abstract

Cryptococcus neoformans is a nonfermentative yeast that requires oxygen for growth. The shaking of culture media achieves good oxygenation, promoting the growth of cryptococci. In this study, three test media (RPMI 1640, RPMI 1640-2% glucose, and buffered yeast nitrogen base ¿BYNB) recommended in the National Committee for Clinical Laboratory Standards M27A standard were examined. Growth abilities and minimum inhibitory concentrations (MICs) in microplates incubated at 35 degrees C for 48 h were determined. The results indicated that shaking and an inoculum size of 10(5) CFU/ml yielded optimal growth of this yeast. Compared to RPMI 1640, supplementation of RPMI 1640 with 2% glucose did not significantly improve growth of C. neoformans and resulted in an 8.7-h delay of exponential growth. Cryptococcal growth in RPMI 1640 at 24 h was notably better than that in RPMI-2% glucose, although by 48 h the growths were comparable. The MIC range of amphotericin B observed for the C. neoformans strains grown in RPMI 1640 with or without glucose was too narrow to allow the separation of susceptible and resistant strains based on clinical outcome. The widest ranges of MICs of flucytosine and fluconazole were obtained with BYNB. This work demonstrates the need for a new antifungal susceptibility test for C. neoformans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639369      PMCID: PMC89690          DOI: 10.1128/AAC.44.2.400-404.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans.

Authors:  J L Rodríguez-Tudela; J Berenguer; J V Martínez-Suárez; R Sanchez
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

3.  Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

Authors:  R A Larsen; S A Bozzette; B E Jones; D Haghighat; M A Leal; D Forthal; M Bauer; J G Tilles; J A McCutchan; J M Leedom
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

4.  Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria.

Authors:  J L Rodriguez-Tudela; J V Martinez-Suárez
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

5.  Susceptibility testing of Cryptococcus neoformans: a microdilution technique.

Authors:  M A Ghannoum; A S Ibrahim; Y Fu; M C Shafiq; J E Edwards; R S Criddle
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

6.  Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.

Authors:  F C Odds; L Vranckx; F Woestenborghs
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Improved medium for fluconazole susceptibility testing of Candida albicans.

Authors:  J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

8.  Oxygen as limiting nutrient for growth of Cryptococcus neoformans.

Authors:  F C Odds; T De Backer; G Dams; L Vranckx; F Woestenborghs
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

  8 in total
  19 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

Authors:  Laura Rodero; Emilia Mellado; A Carolina Rodriguez; Angela Salve; Liliana Guelfand; Pedro Cahn; Manuel Cuenca-Estrella; Graciela Davel; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism.

Authors:  Jose M Ramos; Manuel Cuenca-Estrella; Felix Gutierrez; Matilde Elia; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

4.  Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Ana Alastruey-Izquierdo; Leticia Bernal-Martinez; Isabel Cuesta; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

5.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Analysis of growth characteristics of filamentous fungi in different nutrient media.

Authors:  J Meletiadis; J F Meis; J W Mouton; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

7.  Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds.

Authors:  Calliandra Maria de-Souza-Silva; Fernanda Guilhelmelli; Daniel Zamith-Miranda; Marco Antônio de Oliveira; Joshua Daniel Nosanchuk; Ildinete Silva-Pereira; Patrícia Albuquerque
Journal:  J Vis Exp       Date:  2018-02-14       Impact factor: 1.355

8.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital.

Authors:  Ignacio Gadea; Manuel Cuenca-Estrella; Elena Prieto; Teresa M Diaz-Guerra; Jose I Garcia-Cia; Emilia Mellado; Jose F Tomas; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.

Authors:  Monika Sojakova; Denisa Liptajova; Miroslav Borovsky; Julius Subik
Journal:  Mycopathologia       Date:  2004-02       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.